Varian Medical price target raised to $82 from $73 at RW Baird Baird raised its price target on Varian Medical citing competitor issues which could have positive implications for the company. The company's largest competitor Elektra has been dealt a reimbursement blow which should have positive implications for Varian's soon to be launched Edge SRS system. Shares are Outperform rated.
News For VAR From The Last 14 Days
Check below for free stories on VAR the last two weeks.
Subscribe for More Information